Profile data is unavailable for this security.
About the company
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
- Revenue in USD (TTM)6.00m
- Net income in USD-7.99m
- Incorporated2020
- Employees8.00
- LocationCoya Therapeutics Inc5850 San Felipe St., Suite 500HOUSTON 77057United StatesUSA
- Phone+1 (650) 739-3939
- Fax+1 (302) 636-5454
- Websitehttps://www.coyatherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunic Inc | 0.00 | -97.92m | 114.40m | 77.00 | -- | 1.37 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| FibroGen Inc | 167.49m | -240.46m | 115.39m | 486.00 | -- | -- | -- | 0.6889 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 116.49m | 405.00 | -- | 2.02 | -- | 6.21 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 116.63m | 56.00 | -- | 1.37 | -- | 198.35 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 116.65m | 168.00 | -- | 0.7702 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 117.57m | 13.00 | -- | 9.14 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 118.10m | 37.00 | -- | 0.958 | -- | 113.31 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.38m | 118.45m | 18.00 | -- | 2.32 | -- | -- | -0.6168 | -0.6168 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -43.77 | -45.38 | -46.37 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00008 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Amylyx Pharmaceuticals Inc | 398.00m | -71.10m | 119.35m | 384.00 | -- | 0.3677 | -- | 0.2999 | -1.07 | -1.07 | 5.74 | 4.77 | 0.9644 | 6.74 | 21.00 | 1,036,461.00 | -17.23 | -- | -20.84 | -- | 88.93 | -- | -17.86 | -- | 4.48 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 119.52m | 65.00 | -- | 1.15 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 119.88m | 8.00 | -- | 3.32 | -- | 19.97 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Rezolute Inc | 0.00 | -56.83m | 119.98m | 51.00 | -- | 1.29 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 120.79m | 143.00 | -- | 0.3738 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Vaxart Inc | 7.38m | -82.47m | 124.67m | 109.00 | -- | 1.87 | -- | 16.90 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 125.32m | 22.00 | -- | 1.30 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to Coya Therapeutics Inc's reporting currency: US Dollar USD
25.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Greenlight Capital, Inc.as of 31 Dec 2023 | 1.27m | 8.76% |
| AIGH Capital Management LLCas of 31 Dec 2023 | 1.03m | 7.10% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 841.61k | 5.79% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 110.10k | 0.76% |
| CM Management LLCas of 31 Dec 2023 | 100.00k | 0.69% |
| Worth Venture Partners LLCas of 31 Dec 2023 | 92.67k | 0.64% |
| Geode Capital Management LLCas of 31 Dec 2023 | 92.47k | 0.64% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 52.47k | 0.36% |
| Prelude Capital Management LLCas of 31 Dec 2023 | 35.77k | 0.25% |
| Potomac Capital Management, Inc.as of 31 Dec 2023 | 21.10k | 0.15% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
